Monogram Biosciences

Nucleix Appoints Michael G. Vicari as Chief Commercial Officer

Retrieved on: 
Tuesday, June 6, 2023
Biotechnology, Health, Oncology, Clinical Trials, Smoker, DNA, Senior, Marketing, Monogram Biosciences, Oncocyte, Survival, Liquid biopsy, Cancer, Lung cancer, Biomarker, Genentech, Lung, Organization, GRAIL, Incidence, Patient, Physician, Blood, Sightline (architecture), DNA methylation, Death, Medical imaging

Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, announced the appointment of commercial veteran, Michael G. Vicari, as Chief Commercial Officer.

Key Points: 
  • Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, announced the appointment of commercial veteran, Michael G. Vicari, as Chief Commercial Officer.
  • At Nucleix, Mr. Vicari will build the company’s commercial team, preparing and leading efforts to launch Nucleix’s Lung EpiCheck®, a simple blood test that analyzes changes in DNA methylation patterns to identify lung cancer early.
  • “Mike’s leadership and deep experience in the diagnostic industry make him a great fit as our Chief Commercial Officer, which is a key role as we accelerate our work with Lung EpiCheck,” said Chris Hibberd, Chief Executive Officer at Nucleix.
  • Prior to GRAIL, Mr. Vicari held senior level commercial positions at Inivata, OncoCyte, Sequenom, Monogram Biosciences and Genentech.

C2N Diagnostics, Building on Recent Achievements, Bolsters Executive Team as It Prepares for Commercial Expansion

Retrieved on: 
Monday, April 24, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Health Technology, Daniel, Bachelor, Quest Diagnostics, HEC Paris, Yale School of Management, Diagnosis, Senior, Marketing, Monogram Biosciences, Head, Roche, Yale school, MBA, Research, Alzheimer's disease, Bayer, Biomarker, Washington University in St. Louis, AstraZeneca, Biomedical engineering, Connell, Cardinal Health, Business administration, Genetics, Novartis, Patient, Boğaziçi University, Biomedicine, Medicine, Sanofi, Management, Paris, Acquisition, Memory, Master of Business Administration, Science, Intercontinental

C2N Diagnostics , a leader in advanced brain health diagnostics, which has had a recent series of robust research and funding developments, announces two additions to its executive leadership team.

Key Points: 
  • C2N Diagnostics , a leader in advanced brain health diagnostics, which has had a recent series of robust research and funding developments, announces two additions to its executive leadership team.
  • Both these individuals serve in critical roles as the company scales, increases capacity, and deepens its relationship with patients, providers, payers, and commercial partners.
  • Ozgur Sensoy, who has an established track record of commercialization in the diagnostic and pharmaceutical industries, joins C2N as Senior Vice President of Commercial Operations.
  • We look forward to updating the sector about further important commercial developments as we advance our precision medicine focus.”

SomaLogic Reports Fourth Quarter and Full Year 2022 Financial Results, Announces Director Appointments and Management Evolution

Retrieved on: 
Tuesday, March 28, 2023
Singular, Genomic Health, Executive, General counsel, GeneDx, Monogram Biosciences, Health care, Russell Reynolds Associates, Ted, Labcorp, JPMorgan Chase, Thermo Fisher Scientific, Exact sciences, HTI, Proteomics, M.D, EBITDA, Acquisition, Investment, Sophia Genetics, Medicine, Growth, Webcast, CFO, Research, Adjustment, SomaLogic, Therapy, Foundation Medicine, Tycho, J. P. Morgan, Video game, Management, Pharmaceutical industry, Cryptocurrency, Bookkeeping

His career has spanned a diverse set of roles, including general management, commercial, finance and corporate development.

Key Points: 
  • His career has spanned a diverse set of roles, including general management, commercial, finance and corporate development.
  • Prior to joining SomaLogic, Mr. Taich served as the global leader of the molecular biology business of Thermo Fisher Scientific.
  • The decrease was primarily driven by an increase in sample volume from Human Technopole (HTI) in the fourth quarter of 2022.
  • ET on Tuesday, March 28, 2023 to discuss its fourth quarter 2022 financial results.

Alfred E. Mann Foundation for Scientific Research Strengthens Executive Team with Two Key Appointments

Retrieved on: 
Wednesday, December 15, 2021
Alfred E. Mann, Monogram Biosciences, Elective surgery, Pain, Chemical engineering, Growth, Technology, Industry, Science, Business development, UC, Health, UC Berkeley School of Law, Private practice, Corporation, CEO, Goal, Patient, Alfred, AMF, Lawrence Livermore National Laboratory, Scientific method, Engineering, IP, GLOBE, Diabetes, Ophthalmology, Assistant, UC Berkeley School of Optometry, Pharmaceutical industry, Management, Medicine, Northwestern University, Alcon

LOS ANGELES, Dec. 15, 2021 (GLOBE NEWSWIRE) -- The Alfred E. Mann Foundation for Scientific Research (''AMF''), a non-profit medical device incubator committed to developing and commercializing innovative solutions for significant unmet or poorly met medical conditions, today announced the appointment of two new senior executives. Charles Nelson joins AMF as Chief Operating Officer, and Corey ‘S’ Dishmon as Chief Legal Officer/Chief Business Officer. Mr. Nelson is a thirty-eight-year veteran of the medical device industry and comes to AMF from Alcon, where he oversaw the manufacturing science and technology organization. With over 20 years in healthcare and medical devices, Ms. Dishmon joins AMF from Siemens Healthineers Molecular Diagnostics, where she served as Global General Counsel and Head of Business Development, and Corporate Secretary.

Key Points: 
  • The addition of Charles and Corey not only rounds out our executive leadership team but also underscores our commitment to excellence throughout the organization.
  • I look forward to contributing to the team and their mission to improve lives through medical technology, said Mr. Nelson.
  • These two appointments complete AMFs executive leadership team and are effective immediately.
  • Founded in 1985 by serial healthcare entrepreneur Alfred E. Mann, the Alfred Mann Foundation for Scientific Research's (AMF) mission is to develop and commercialize innovative solutions for significant unmet or poorly met medical conditions.

Autolus Therapeutics announces the appointment of Dr. William D. Young as a Non-Executive Director

Retrieved on: 
Monday, November 15, 2021
Eli Lilly and Company, Safety, CD19, Cancer, Lymphatic system, ALL, Private Securities Litigation Reform Act, National academy, Therapy, III, Engineering, Monogram Biosciences, BioMarin Pharmaceutical, Security (finance), MBA, MRD, Acute lymphoblastic leukemia, Senior advisor, NanoString Technologies, Eli Lilly, COVID-19, CAR, Forward-looking statement, Annual report, Purdue University, Risk, Board, Biotechnology, U.S. Securities and Exchange Commission, UCL, GLOBE, Company, LabCorp, Toxicity, Monogram, Board of directors, Vertex Pharmaceuticals, Nasdaq, Patient, Cell, National Academy of Engineering, Adult, Pharmaceutical industry, Management, Vaccine

Dr. Young will serve as a Class III director, with an initial term expiring at Autolus 2024 annual general meeting.

Key Points: 
  • Dr. Young will serve as a Class III director, with an initial term expiring at Autolus 2024 annual general meeting.
  • Dr. Young also currently serves as a member of the Board of Directors of Nanostring Technologies (Chairman), Theravance Biopharma and Praxis Precision Medicine.
  • He has also served on a number of other biotech boards such as BioMarin Pharmaceutical and Vertex Pharmaceuticals.
  • I am delighted to join the board of Autolus at such a pivotal time in the Companys development, said Bill Young.

Multiple Abstracts Highlighting Assembly Biosciences’ Hepatitis B Core Inhibitor Development Programs Accepted for Presentation at the 2020 AASLD The Liver Meeting Digital Experience™

Retrieved on: 
Monday, November 2, 2020
Medical specialties, Hepadnaviridae, Clinical medicine, Infectious diseases, Infectious causes of cancer, Hepatitis B, Hepatitis, Monogram Biosciences

This annual meeting of the American Association for the Study of Liver Diseases(AASLD) will be hosted virtually November 13-16, 2020.

Key Points: 
  • This annual meeting of the American Association for the Study of Liver Diseases(AASLD) will be hosted virtually November 13-16, 2020.
  • In the ongoing Phase 2 open-label extension trial, Assembly Bio has begun transitioning patients off therapy, to then monitor for sustained virologic response (SVR).
  • Assembly Bios HBV portfolio also includes two more potent, second-generation candidates ABI-H2158 in Phase 2 development, and ABI-H3733, in Phase 1 development.
  • Assembly Biosciences, Inc.is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome.

Janssen Reports Switching to SYMTUZA™ Results in Maintained High Virologic Suppression and No Resistance Development up to 96-Weeks in Virologically Suppressed Adults with HIV-1

Retrieved on: 
Wednesday, October 3, 2018
Monogram Biosciences, Hepatotoxins

After initial increases between baseline through to week 48, the lipid profile among D/C/F/TAF patients remained stable thereafter.

Key Points: 
  • After initial increases between baseline through to week 48, the lipid profile among D/C/F/TAF patients remained stable thereafter.
  • Over 44 weeks, in this late-switch group, serious adverse events and adverse event-related discontinuations occurred in 6% (21/352) and 2% (7/352) of adults respectively while on SYMTUZA.
  • In this group, the virologic suppression and virologic failure rates were 94% (330/352) and 2% (6/352) respectively at week 96 (per FDA-Snapshot).
  • Your healthcare provider may need to do tests to check your liver enzymes before and during treatment with SYMTUZA.